Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Clinicians(Electronic Edition) ›› 2026, Vol. 20 ›› Issue (06): 424-432. doi: 10.3877/cma.j.issn.1674-0785.2026.06.003

• Clinical Research • Previous Articles    

Efficacy and safety of hypofractionated radiotherapy in pulmonary oligometastases from non-small cell lung cancer

Yilong Mao, Lei Liu, Leilei Guo, Chencong Li, Shuying Kong, Yiqian Wang†()   

  1. Department of Radiation Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian 116000, China
  • Received:2026-05-15 Online:2026-06-30 Published:2026-11-16
  • Contact: Yiqian Wang

Abstract:

Objective

To evaluate the efficacy and safety of hypofractionated radiotherapy (HFRT) in the treatment of pulmonary oligometastases originating from non-small cell lung cancer (NSCLC).

Methods

We retrospectively enrolled 141 patients with advanced NSCLC who developed isolated pulmonary oligometastatic progression following first-line systemic therapy at the First Affiliated Hospital of Dalian Medical University between November 2019 and June 2023. The cohort comprised 93 males and 48 females, with a median age of 66 years. Propensity score matching (PSM) was performed using a caliper of 0.2 at a 1∶1 ratio, yielding 82 patients who were allocated to either the HFRT group (n=41) or the standard-of-care (SOC) group (n=41), based on whether they received HFRT to pulmonary metastases. All patients received systemic regimens in accordance with guideline-recommended standard care; those in the HFRT group additionally underwent volumetric modulated arc therapy (VMAT). We compared short-term response, progression-free survival (PFS), overall survival (OS), and safety profiles between the two groups. Survival rates were estimated using the Kaplan-Meier method, and multivariate prognostic analyses were conducted using Cox regression models.

Results

After matching, each group consisted of 41 patients. With a median follow-up of 32.1 months, the HFRT group demonstrated significantly better short-term response (P=0.038), PFS (P=0.037), and OS (P=0.038) compared with the SOC group. Independent prognostic factors for PFS included the addition of HFRT and the type of systemic therapy; for OS, independent factors were HFRT use, systemic regimen, and the number of metastatic lesions. Adverse events were manageable in both treatment arms.

Conclusion

In patients with advanced NSCLC presenting with pulmonary oligoprogression after first-line systemic therapy—particularly those with driver-gene-negative tumors receiving chemo-immunotherapy—the addition of HFRT to metastatic lesions confers favorable outcomes with an acceptable safety profile.

Key words: Non-small cell lung cancer, Oligoprogression, Pulmonary oligometastasis, Hypofractionated radiotherapy, Prognostic factors

京ICP 备07035254号-20
Copyright © Chinese Journal of Clinicians(Electronic Edition), All Rights Reserved.
Tel: 010-57830845 E-mail: zhlcyszz@cma.org.cn
Powered by Beijing Magtech Co. Ltd